Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 113, Issue -, Pages 8-17Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2017.02.021
Keywords
CD30; Solid tumor; Non-hematopoetic; Non-lymphomatous; Ki-1; Brentuximab vedotin; Antibody-drug-conjugate
Categories
Funding
- National Cancer Institute, National Institutes of Health, Bethesda, MD [P30 CA023074]
- NIH [NIHT35 HL07479]
Ask authors/readers for more resources
Background: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. FDA approval for BV includes relapsed and refractory HL and sALCL. The CD30 antigen also has been identified in many solid tumors, predominantly of germ cell origins and early clinical data is promising. Objective: Perform a focus literature review evaluating the prevalence of the CD30 antigen among non-lymphomatous tumors with a potential correlate for CD30 targeted therapy. Eligibility criteria: Inclusion criteria: all retrospective reviews and case reports citing CD30 positivity or negativity in non-lymphomatous malignancies in which data were presented based on location. Exclusion criteria: studies with hemato poetic malignancies, cutaneous malignancies, non-human populations, and non-english publications. Included studies: A total of 119 articles met these criteria and are summarized in this manuscript. Conclusion: The CD30 antigen has shown variable prevalence among non-hematopoetic tumors, most notably among germ cell tumors and mesothelioma. With additional, preclinical and properly powered clinical studies, CD30 targeted therapy such as that of BV, alone or in combination with other agents may prove to be a strong candidate in the treatment of various CD30(+) malignancies. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available